Jean-Jacques Garaud – CEO, Inotrem, France

Inotrem is a French biotech company developing a novel approach to target inflammatory diseases based on the TREM-1 pathway. Its CEO, Dr Jean-Jacques Garaud explains why he decided to leave Big Pharma for biotech, lays out Inotrem’s recent milestones, and outlines his internationalization strategy.  
The TREM-1 pathway can be used to develop treatments for different indications besides septic shock, including cardiovascular diseases and chronic inflammatory conditions, which could be interesting to investors or Big Pharma
Become a PharmaBoardroom Member for free to access this content
Join the 20,000+ pharmaceutical professionals who already subscribe to PharmaBoardroom
Already a member? Sign In

Related Interviews

Latest Report